Clinical Trial Update: A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating inhaled umeclidinium (UMEC) in COPD patients using a novel dry powder inhaler; study completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• umeclidinium (UMEC) (umeclidinium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2019-06-28